PMID- 36134681 OWN - NLM STAT- MEDLINE DCOM- 20220923 LR - 20220928 IS - 1526-2359 (Electronic) IS - 1073-2748 (Print) IS - 1073-2748 (Linking) VI - 29 DP - 2022 Jan-Dec TI - Prognostic Factors for Clinical Outcomes in Patients with Newly Diagnosed Advanced-stage Hodgkin Lymphoma: A Nationwide Retrospective Study. PG - 10732748221124865 LID - 10.1177/10732748221124865 [doi] LID - 10732748221124865 AB - INTRODUCTION: While Hodgkin lymphoma (HL) is mostly curable, outcomes for advanced-stage HL remain unsatisfactory. The International Prognostic Score and its modifications were developed to predict HL prognosis; however, more straightforward prognostic factors are needed. This study aimed to identify simpler prognostic factors for advanced-stage newly diagnosed HL (NDHL). METHODS: This retrospective study used the Taiwan National Health Insurance Research Database and the Taiwan Cancer Registry. Patients with advanced-stage NDHL receiving ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or ABVD-like regimens between 2009 and 2016 were enrolled. Cox proportional hazards models were used to identify prognostic factors for the time to next treatment (TTNT) and overall survival (OS). We used the time-dependent area under the receiver operating characteristic curve (AUROC) to evaluate model performance. RESULTS: The study included 459 patients with advanced-stage NDHL. A bimodal age distribution (peaks 20-44 and >65 years) was observed. Over a median follow-up of 4.7 years, the complete remission and OS rates were 52% and 76%, respectively. Age >/=60 years (adjusted hazard ratio [aHR]: 1.73, 95% confidence interval [CI]: 1.23-2.43), extranodal involvement (1.40, 1.05-1.87), B symptoms (1.53, 1.13-2.06), and Charlson Comorbidity Index (CCI) >/=1 (1.49, 1.08-2.06) were significantly associated with a shorter TTNT. The time-dependent AUROC was .65. With a time-dependent AUROC of .81, age >/=60 years (4.55, 2.90-7.15) and CCI >/=1 (1.86, 1.18-2.91) were risk factors for worse OS. CONCLUSION: Older age and more comorbidities were risk factors for an inferior OS in advanced-stage NDHL, while older age, extranodal involvement, B-symptoms, and higher CCI were significantly associated with disease relapse. FAU - Jerry Teng, Chieh-Lin AU - Jerry Teng CL AD - Division of Hematology/Medical Oncology, Department of Medicine, 40293Taichung Veterans General Hospital, Taichung, Taiwan. AD - Department of Life Science, Tunghai University, Taichung, Taiwan. AD - School of Medicine, Chung Shan Medical University, Taichung, Taiwan. AD - Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. AD - Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan. AD - Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan. FAU - Tan, Tran-Der AU - Tan TD AD - Department of Hematology and Medical Oncology, 59087Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan. FAU - Pan, Yun-Yi AU - Pan YY AD - Graduate Institute of Clinical Pharmacy, College of Medicine, 33561National Taiwan University, Taipei, Taiwan. FAU - Lin, Yu-Wen AU - Lin YW AD - Graduate Institute of Clinical Pharmacy, College of Medicine, 33561National Taiwan University, Taipei, Taiwan. FAU - Lien, Pei-Wen AU - Lien PW AD - Takeda Pharmaceuticals Taiwan, Ltd., Taipei, Taiwan. FAU - Chou, Hsin-Chun AU - Chou HC AD - Takeda Pharmaceuticals Taiwan, Ltd., Taipei, Taiwan. FAU - Chen, Peng-Hsu AU - Chen PH AD - Takeda Pharmaceuticals Taiwan, Ltd., Taipei, Taiwan. FAU - Lin, Fang-Ju AU - Lin FJ AUID- ORCID: 0000-0002-8249-7481 AD - Graduate Institute of Clinical Pharmacy, College of Medicine, 33561National Taiwan University, Taipei, Taiwan. AD - School of Pharmacy, College of Medicine, 33561National Taiwan University, Taipei, Taiwan. AD - Department of Pharmacy, 33561National Taiwan University Hospital, Taipei, Taiwan. LA - eng PT - Journal Article PL - United States TA - Cancer Control JT - Cancer control : journal of the Moffitt Cancer Center JID - 9438457 RN - 11056-06-7 (Bleomycin) RN - 5V9KLZ54CY (Vinblastine) RN - 7GR28W0FJI (Dacarbazine) RN - 80168379AG (Doxorubicin) SB - IM MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bleomycin/therapeutic use MH - Dacarbazine/adverse effects MH - Doxorubicin/therapeutic use MH - *Hodgkin Disease/drug therapy/pathology MH - Humans MH - Middle Aged MH - Neoplasm Staging MH - Prognosis MH - Retrospective Studies MH - Treatment Outcome MH - Vinblastine/therapeutic use PMC - PMC9511302 OTO - NOTNLM OT - hodgkin lymphoma OT - overall survival OT - prognostic factor OT - time to next treatment COIS- Declaration of Conflicting Interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Chieh-Lin Jerry Teng received an honorarium and consulting fees from Novartis, Roche, Takeda, Johnson & Johnson, Amgen, BMS Celgene, Kirin, AbbVie, and MSD. Hsin-Chun Chou and Peng-Hsu Chen are employees of Takeda Pharmaceuticals Taiwan, Ltd. Pei-Wen Lien was an employee of Takeda Pharmaceuticals Taiwan, Ltd at the time of this study. EDAT- 2022/09/23 06:00 MHDA- 2022/09/24 06:00 PMCR- 2022/09/22 CRDT- 2022/09/22 06:14 PHST- 2022/09/22 06:14 [entrez] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/09/24 06:00 [medline] PHST- 2022/09/22 00:00 [pmc-release] AID - 10.1177_10732748221124865 [pii] AID - 10.1177/10732748221124865 [doi] PST - ppublish SO - Cancer Control. 2022 Jan-Dec;29:10732748221124865. doi: 10.1177/10732748221124865.